Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sibutramine in Binge-Eating Disorder
NCT00402584Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Aug 2000
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in binge eating disorder (BED) and obesity comparing Sibutramine with Placebo (2 arms). Primary endpoint: Frequency of binge eating episodes at 6 months. Started Aug 2000; status: completed.
02
Drugs
sibutramine
03
Conditions
binge eating disorder (BED)obesity
Beyond the preview
Go deeper on NCT00402584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00402584.